BJC reports最新文献

{"title":"Stromal collagen IV expression and risk of breast cancer death in ductal carcinoma in situ.","authors":"Gunilla Rask, Malin Jansson, Johan Svensson, Rebecca Wiberg, Fredrik Wärnberg, Ola Billing, Charlotta Wadsten, Malin Sund","doi":"10.1038/s44276-025-00191-w","DOIUrl":"https://doi.org/10.1038/s44276-025-00191-w","url":null,"abstract":"<p><strong>Background: </strong>Current treatment for ductal carcinoma in situ (DCIS) of the breast is generic, due to lack of risk stratification tools. We investigate the correlation between expression of collagen IV in the breast and risk of dying of breast cancer. We also explore the effect of collagen IV in vitro.</p><p><strong>Methods: </strong>Tissue microarrays from a cohort of women treated for DCIS who later died from breast cancer (n = 43) or were still alive (n = 119), were analysed for collagen IV by immunohistochemistry. Oestrogen receptor positive (ER+), triple negative and human epidermal growth factor receptor 2 amplified (HER2+) cell lines were cultured with and without collagen IV.</p><p><strong>Results: </strong>High expression of stromal collagen IV correlated with increased odds of dying of breast cancer (OR 2.50; 95% CI 1.16-5.39). This association remained when adjusting for tumour size, margin status, comedo necrosis and progesterone receptor negativity (PR-) (OR 4.27; 95% CI 1.64-11.1). Triple negative breast cancer cell lines migrated quicker on collagen IV-coated than on uncoated surfaces. By contrast, collagen IV coating did not affect ER+ and HER2+ cell lines.</p><p><strong>Conclusions: </strong>Abundance of stromal collagen IV increases risk of dying in breast cancer after DCIS, and collagen IV can promote cell motility in vitro.</p>","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"73"},"PeriodicalIF":0.0,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145351085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The transcription factor Blimp-1 is suppressed by SLAMF1 and drives Treg cell-mediated immune evasion in non-small cell lung cancer.","authors":"Susetta Finotto, Denis I Trufa, Sonja Trump, Laura Neurath, Katja Hohenberger, Patrick Tausche, Nicole Neurath, Sviatoslav Tsiumpala, Susanne Mittler, Andreas Wild, Elvedina Nendel, Horia Sirbu, Arndt Hartmann","doi":"10.1038/s44276-025-00184-9","DOIUrl":"https://doi.org/10.1038/s44276-025-00184-9","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors targeting the interaction between PD1 and PDL1 are effective for immunotherapy in non-small cell lung cancer (NSCLC). However, only subgroups of patients respond to therapy, suggesting the existence of resistance mechanisms.</p><p><strong>Methods: </strong>In this study, we analyzed post-surgery lung tissues and peripheral blood cells from patients with Non Small Cell Lung Cancer (NSCLC) and control subjects by using western blot, immunohistochemistry, ELISA, multiplex cytokine, and qPCR analysis.</p><p><strong>Results: </strong>Here, we found progressively increased Blimp1 expression in the tumoral region of NSCLC patients, where Slamf1 significantly decreased, and it inversely correlated with Blimp1. In PBMCs, Blimp1 was expressed in CD8+ T cells but predominantly in immunosuppressive Foxp3+ Treg cells or after targeting of the T cell activator Slamf1. Anti-CD3/CD28 induced IL-6 and IL-10, an immunosuppressive gene induced by Blimp1, in the supernatants of PBMCs from patients with NSCLC. Targeting PD1 in PBMCs reduced Blimp1.</p><p><strong>Conclusions: </strong>Here, we identify a key role of the transcription factor Blimp1 for immune evasion in NSCLC. Thus, targeting Blimp1 emerges as a novel concept to improve current lung cancer immunotherapies and to suppress immune evasion in lung cancer.</p>","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"74"},"PeriodicalIF":0.0,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145351118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"KRAS and NRAS mutations in Nordic population-based and real-world metastatic colorectal cancer cohorts.","authors":"Emerik Osterlund, Ari Ristimäki, Luís Nunes, Soili Kytölä, Sonja Aho, Eetu Heervä, Aki Uutela, Kaisa Lehtomäki, Hanna Stedt, Päivi Halonen, Joel Kontiainen, Timo Muhonen, Raija Kallio, Jari Sundström, Annika Ålgars, Raija Ristamäki, Lasse Nieminen, Halfdan Sorbye, Per Pfeiffer, Tapio Salminen, Arno Nordin, Annamarja Lamminmäki, Markus J Mäkinen, Tobias Sjöblom, Helena Isoniemi, Bengt Glimelius, Pia Osterlund","doi":"10.1038/s44276-025-00188-5","DOIUrl":"https://doi.org/10.1038/s44276-025-00188-5","url":null,"abstract":"<p><strong>Background: </strong>KRAS and NRAS mutations (mt) are drivers in metastatic colorectal cancer (mCRC). We studied frequencies, characteristics, treatments, and outcomes of different KRASmt and NRASmt in population-based and real-world settings.</p><p><strong>Methods: </strong>Three Nordic cohorts were combined and molecularly characterised for KRAS, NRAS, and BRAF-V600E hotspot mutations.</p><p><strong>Results: </strong>Of 2649 mCRC patients, 2118 were molecularly classified. KRASmt were seen in 49%, NRASmt in 4%, RAS&BRAFwt in 33%, and BRAF-V600Emt in 14%. No differences in clinical characteristics were observed between KRASmt and NRASmt. Median overall survival (OS) was longest among RAS&BRAFwt, intermediate among KRASmt and NRASmt, and shortest among BRAF-V600Emt (28.3 vs 21.4 vs 26.3 vs 9.2 months, respectively). Among the eight most common KRASmt, the only clinical difference was that KRAS-G12S had more distant lymph node metastases (38% vs 18-27%, p = 0.041). KRAS-G12S had shorter OS than KRAS-G12V, KRAS-G12C, KRAS-G12A, and KRAS-G13D. The differences were smaller in treatment groups but withstood in multivariable models. The three most common NRASmt did not differ clinically.</p><p><strong>Conclusion: </strong>KRASmt and NRASmt are seen in 49% and 4% of mCRC, respectively. No clinically relevant differences were observed between different RASmt. KRASmt is a common subgroup for which the outcome hopefully can be improved with newly developed drugs.</p>","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"72"},"PeriodicalIF":0.0,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145351105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Too much or too little? The trajectory of systemic anti-cancer treatment throughout the last year of life of lung cancer patients in Norway.","authors":"Steinar Solberg, Kathinka Schmidt Slørdahl, Marianne Aanerud, Odd Terje Brustugun, Bjørn Henning Grønberg, Nina Helbekkmo, Åslaug Helland, Yngvar Nilssen","doi":"10.1038/s44276-025-00183-w","DOIUrl":"10.1038/s44276-025-00183-w","url":null,"abstract":"<p><strong>Background: </strong>The use of systemic anti-cancer treatment (SACT) at the end of life (EOL) is controversial. The evidence and detailed description of the dynamics of its use are deficient, especially after the introduction of targeted therapies and immunotherapy.</p><p><strong>Methods: </strong>Clinical information about lung cancer patients dying in the years 2020-2023 was extracted from the Cancer Registry of Norway. Available data on intravenous and oral SACT enabled the calculation of the proportion of patients who received SACT each of the 360 days before death.</p><p><strong>Results: </strong>A total of 8953 patients were eligible for this study. At day 30, 7, and 1 before death, 8.9%, 1.3%, and 0.4% respectively, received SACT. The reduction was mainly caused by reduced use of chemotherapy and immunotherapy closer to death. Independent predictors for receiving SACT at day 30 before death were young age, male sex, small-cell lung cancer, short time from diagnosis to death, and good performance status.</p><p><strong>Conclusion: </strong>The presented low use of SACT at EOL has been achieved in a population where good survival has been documented. Patients with poor performance status and older age received less SACT than patients with good performance status and younger age.</p>","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"70"},"PeriodicalIF":0.0,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12511628/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145260525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Germline JAK2 R564Q variants presenting as hereditary thrombocytosis: case report.","authors":"Stephanie Franco, Kinga Krawiec, Piotr Strzalka, Lucy A Godley","doi":"10.1038/s44276-025-00186-7","DOIUrl":"10.1038/s44276-025-00186-7","url":null,"abstract":"<p><p>Myeloproliferative neoplasms (MPNs) are classically attributed to somatic variants in JAK2, CALR, and MPL, with epidemiologic studies demonstrating an increased risk for MPNs within first-degree relatives. Germline variants associated with MPN predisposition include rare variants of low population frequency/high penetrance alleles, often in JAK2, resulting in non-clonal MPN-like disorders, including hereditary thrombocytosis (HT). The first activating germline JAK2 variant encoding a residue other than V617F identified in association with a hereditary MPN-like syndrome was c.1691 G > A, p.Arg564Gln (R564Q), a gain-of-function missense variant. Here, we present the cases of three unrelated individuals with HT and the germline JAK2 R564Q variant, two of whom were tested in 2023, and received clinical reports classifying the variant as a variant of uncertain significance, and the third, tested more recently from a different laboratory, which classified the variant as likely pathogenic (LP). We propose that germline testing should be offered at minimum to MPN patients presenting at a young age, those with apparent familial clustering, and those with triple negative/idiopathic disease. These three cases provide additional segregation data that should sway consensus regarding the pathogenicity of this variant toward LP and resolve the conflicting classifications for this variant in ClinVar.</p>","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"69"},"PeriodicalIF":0.0,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12501285/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145240855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Attenuation of malignant phenotype of glioblastoma following a short course of the pro-oxidant combination of Resveratrol and Copper.","authors":"Chaitra Bandiwadekar, Leimarembi Devi Naorem, Aliasgar V Moiyadi, Vikas Singh, Prakash Shetty, Sridhar Epari, Harshali Tandel, Roohi Yelukar, Disha Poojary, Gorantla V Raghuram, Snehal Shabrish, Pratik Chandrani, Indraneel Mittra","doi":"10.1038/s44276-025-00177-8","DOIUrl":"10.1038/s44276-025-00177-8","url":null,"abstract":"<p><strong>Background: </strong>We investigated a novel therapeutic approach to glioblastoma (GBM) that targets cell-free chromatin particles (cfChPs) that are released from dying GBM cells and aggravate the oncogenic phenotype of living GBM cells. cfChPs can be deactivated by oxygen radicals (OR) generated upon oral administration of the nutraceuticals Resveratrol (R) and Copper (Cu).</p><p><strong>Methods: </strong>Ten patients with glioblastoma awaiting surgery were administered 5.6 mg of Resveratrol (R) and 560 ng of Copper (Cu) four times a day for an average of 11.6 ± 5.37 days. Another ten patients who did not receive R-Cu acted as controls. A tissue sample was taken at operation for analysis.</p><p><strong>Results: </strong>R-Cu treatment led to marked deactivation of cfChPs that were present in the tumour microenvironment, which was accompanied by a highly significant down-regulation in Ki-67, nine hallmarks of cancer, six immune check-points and three stem cell biomarkers as revealed by immuno-fluorescence analysis. Transcriptome sequencing detected marked upregulation of pro-apoptotic and down-regulation of anti-apoptotic genes. Also detected was down-regulation of PVRIG-2P, a homologue of immune checkpoint receptor PVRIG, which is a functional analogue of PD-L1.</p><p><strong>Conclusions: </strong>These results suggest that a simple, non-toxic and inexpensive combination of the commonly used nutraceuticals Resveratrol and Copper can have a profound effect on the aggressive phenotype of GBM. Further studies are warranted to evaluate whether prolonged treatment with R-Cu might induce the tumours to adopt a benign phenotype.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier: CTRI/2020/10/028476 ( https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NDY2Mzc=&Enc=&userName=Aliasgar ).</p>","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"68"},"PeriodicalIF":0.0,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12484550/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145202649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the significance of combining PD-L1 and TILs as biomarkers in non-small cell lung cancer patients treated with immunotherapy: a systematic review.","authors":"Y Derraze, S M S Hashemi, E B Ulas, K A Ziesemer, B Lissenberg-Witte, T Radonic, I Bahce","doi":"10.1038/s44276-025-00174-x","DOIUrl":"10.1038/s44276-025-00174-x","url":null,"abstract":"<p><p>In advanced non-small cell lung cancer (NSCLC), programmed death-ligand 1 (PD-L1) expression is a well-established but suboptimal biomarker for predicting response to immune checkpoint inhibitors (ICIs). Tumor-infiltrating lymphocytes (TILs), particularly CD8+ subsets, have demonstrated potential as complementary biomarker. Despite existing data on each biomarker individually, the combined effect is not fully understood. A systematic search of Ovid/Medline, Embase, and Web of Science identified studies on CD8+ TILs and PD-L1 in NSCLC patients treated with ICIs. The primary outcomes were progression-free survival (PFS) and overall survival (OS). Secondary endpoints included objective response rate (ORR) and durable clinical benefit (DCB). Study quality was assessed using the Newcastle-Ottawa Scale. Thirteen studies (2490 patients) were included. PD-L1 expression was associated with longer PFS in 6 of 8 studies (HR: 0.67, 95% CI: 0.49-0.90) but did not significantly correlate with OS. TILs alone showed no significant predictive value for PFS or OS. However, combining both biomarkers provided the strongest predictive value for PFS (HR: 0.39, 95% CI: 0.27-0.57) and OS (HR: 0.42, 95% CI: 0.31-0.56). Combining PD-L1 and TILs may more effectively predict PFS and OS than either biomarker alone, though their clinical application remains complex.</p>","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"65"},"PeriodicalIF":0.0,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454632/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145126870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment with checkpoint inhibitors for unresectable non-metastatic mismatch repair deficient intestinal cancer; a case series.","authors":"O J A Figaroa, I T Spaanderman, R S A Goedegebuure, G M Cirkel, F J F Jeurissen, G J Creemers, A D Bins, J Tuynman, T E Buffart","doi":"10.1038/s44276-025-00171-0","DOIUrl":"10.1038/s44276-025-00171-0","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) is a common malignancy, with mismatch repair deficient (dMMR) CRC comprising approximately 15% of non-metastatic cases. dMMR tumors generate neoantigens making them highly responsive to immune checkpoint inhibitors, this became the first-line treatment for metastatic dMMR CRC. Aim of this study is to evaluate the efficacy of single-agent Pembrolizumab for patients with locally advanced unresectable dMMR intestinal cancers.</p><p><strong>Methods: </strong>We retrospectively reviewed patients with locally advanced unresectable dMMR/MSI-H CRC or small intestinal adenocarcinoma (SIA) who received PD-1 inhibitors between January 2022 and December 2023 at 1 University Medical Center and 3 regional hospitals and analyzed the treatment efficacy and survival outcomes.</p><p><strong>Results: </strong>Response rate was 78% after at least one cycle of Pembrolizumab with conversion to resection in nearly 40%. Patients who underwent primary tumor resection had a two-year overall survival (OS) of 100%, whereas those without resection had significantly lower OS (42%), progression-free survival (PFS; 36%), and cancer-specific survival (CSS; 71%) at two years. In total, 22% of the patients discontinued the treatment due to toxicity.</p><p><strong>Discussion: </strong>Although the observed response rates of Pembrolizumab are high, there is still room for improvement. Dual immune checkpoint inhibitors might be needed for these patients to improve outcomes.</p><p><strong>Clinical trial registration: </strong>A selection of patients included in this study were part of the ATAPEMBRO study, a single-centre, open label, phase 1-2 study (NCT04014530).</p>","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"67"},"PeriodicalIF":0.0,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454659/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145126939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Observation of PICALM::MLLT10-rearrangement and coincidental EZH2 mutations in a patient with acute myeloid leukemia: A case report and review of the literature.","authors":"Christian Rausch, Ulrike Bacher, Joelle Tchinda, Michèle Hoffmann, Katja Seipel, Thomas Pabst","doi":"10.1038/s44276-025-00175-w","DOIUrl":"10.1038/s44276-025-00175-w","url":null,"abstract":"<p><p>Acute Myeloid Leukemia (AML) with rearranged PICALM::MLLT10 is a rare and poorly characterized entity. Here, we describe a patient with this rearrangement, and compare this case to the literature. We observed a trend towards young age, male sex, extramedullary involvement (particularly mediastinal myelosarcoma), trisomy 4, trisomy 19 and aberrant CD7-expression. It was suggested that upregulation of DOT1l or BMI1 is a key effector for subsequent leukemogenesis. However, molecular data are not available for most published cases. Interestingly, two different EZH2-mutations were detected in our case, while generally being rare in AML, which is concordant with recent reports on the occurrence of EZH2mut in this AML subtype. As a synergistic effect of BMI1 and EZH2 has already been demonstrated in other neoplasms, we hypothesize that acquiring an EZH2 mutation might be a crucial proliferation advantage in PICALM::MLLT10 positive cells. This may explain the high percentage of EZH2 mutated cases in this entity, but also supports the hypothesis of BMI1-mediated leukemogenesis.</p>","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"66"},"PeriodicalIF":0.0,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454637/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145126922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to: Survival after risk-reducing mastectomy in young BRCA1 carriers with breast cancer.","authors":"Virginia Delucchi, Matteo Lambertini, Eva Blondeaux","doi":"10.1038/s44276-025-00179-6","DOIUrl":"10.1038/s44276-025-00179-6","url":null,"abstract":"<p><p>We address methodological considerations in evaluating risk-reducing mastectomy among young BRCA carriers with prior history of breast cancer, emphasizing time-dependent analysis, realistic assumptions on mortality and contralateral breast cancer risk, and appropriate confounder adjustment as ways to improve accuracy in survival outcome estimates.</p>","PeriodicalId":519964,"journal":{"name":"BJC reports","volume":"3 1","pages":"62"},"PeriodicalIF":0.0,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12449466/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145093401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}